India's Biocon to list research services unit
India’s Biocon plans to spin off its drug research arm Syngene International via an offer for sale of secondary shares and is in the process of appointing bankers.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts